Target PharmaSolutions
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2023 |
---|---|---|---|---|---|
Revenues | 8.5m | 9.0m | 10.9m | 11.4m | 18.8m |
% growth | - | 6 % | 21 % | 5 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$640k | Seed | ||
N/A | Series A | ||
* | €2.0m | Seed | |
Total Funding | €2.6m |
Related Content
Recent News about Target PharmaSolutions
EditTarget RWE specializes in designing and sponsoring real-world evidence (RWE) communities comprising large, disease-specific patient cohorts. These cohorts provide regulatory-grade data and insights, which are crucial for informing high-quality drug development solutions. The company serves pharmaceutical companies, regulatory agencies, and healthcare providers, operating primarily in the healthcare and pharmaceutical markets. Target RWE's business model revolves around offering custom data solutions, consulting services, and biospecimen samples. Revenue is generated through partnerships and service contracts with clients who require tailored data solutions for drug development and regulatory purposes.
Keywords: real-world evidence, drug development, regulatory-grade data, patient cohorts, healthcare, pharmaceutical, custom data solutions, consulting services, biospecimen samples, disease-specific.